Raffinadery29
This is the first retinoid that can safely treat acne on your face, chest, shoulders and back
As for the topic of acne, the conversation is usually about ways to treat it or how it can lead to anxiety, depression and low self-esteem.1 It is usually about the desigmatization of a skin concern that is so common that it affects up to 50 . annually million Americans.2 It is usually about facial acne. According to the certified dermatologist, dr. Julie Harper, body acne is not as much discussed as acne on the face – despite the fact that it is fairly common. For Dr Harper, it affects more than half of her patients who have acne on their face.3 “Truncal [the medical term for ‘chest, shoulders, and back’] acne can present its own challenges, ”she explains. ‘There is a difference in the treatment of acne on the face and waste, but the difference in the treatment approach is historically not based on evidence or data. Finally, we tend to treat acne on the trunk. It tends to be out of sight, out of mind. For this reason, dr. Harper that there have been no proven treatments for acne in the body – so far the AKLIEF® (trifarotene) cream from Galderma, 0.005%, has been indicated for the treatment of acne that is safe for the face, chest, shoulders and back. 4 It is an innovative prescription retinoid – the first retinoid molecule to be approved by the FDA for more than 20 years for the treatment of acne.5 The retinoid molecule (active ingredient) is tripharotene, which specifically targets the important factors that cause acne. “This selectivity of tripharotene means that the product is powerful even in low concentrations,” says Dr. Harper, who is also a paid Galderma spokesman. 7 “This low concentration gives us comfort from a safety point of view to use on larger surfaces, such as the chest and back.” 4 After consulting a dermatologist and prescribing AKLIEF Cream, use it as your doctor tells you, and serve a thin layer (one pump for the face, two pumps for chest, shoulders, and back) and gem to lighten the sun by using sunscreen and protective clothing – after that you can see acne improve for two weeks.4 ‘ [your acne] is mild to moderate or severe, or on the face or torso, it can be treated, ”says dr. Harper. IMPORTANT SAFETY INFORMATION: Indication: AKLIEF ® (tripharotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. treated with AKLIEF Cream was irritation of the application site, itching of the application site (itching) and sunburn. Warnings / Precautions: Patients using AKLIEF Cream may experience erythema, scaling, dryness and stinging / burning. Use a moisturizer from the beginning of treatment, and, if appropriate, depending on the severity of these side effects, reduce the frequency of application of AKLIEF Cream, discontinue or discontinue use. Avoid applying AKLIEF Cream on cuts, abrasions or an eczema or sunburned skin. Use of “wax” as a removal method should be avoided on skin treated with AKLIEF Cream. Reduce exposure to sunlight and sun lamps. Use sunscreen and protective clothing on treated areas when exposure can not be avoided. You are encouraged to report adverse drug side effects to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. All trademarks are the property of their respective owners. This information is not intended as medical advice. Talk to your doctor about your medical problems. 1 American Academy of Dermatology. Acne can affect your skin more than anything else. https://www.aad.org/public/diseases/acne-and-rosacea/emotional-health-effects-of-acne. Visited August 23, 2019. 2 Chiu A. et al. The response of skin disease to stress. Amer. Medical association. 2003. 139: 897-900.3 Del Rosso JQ et al. A closer look at truncal acne vulgaris: appearance, severity and clinical importance. J Dermatol. 2007; 6: 597-600.4 Tan J, Thiboutot D, Popp G, Gooderham M, Lynde C, et al. Randomized Phase 3 evaluation of trifarotene 50 μg / g cream treatment of moderate facial and blunt acne. J Am Acad Dermatol. 2019. DOI: https://doi.org/10.1016/j.jaad.2019.02.044.5 British Association of Dermatologists. Topical tripharotene: a new retinoid. Br J Dermatol. 2018; 179: 231-232. 6 Fisher GJ, et al. J Biol Chem 1994; 269 (32): 20629-35. 7Aubert J, Piwnica D, Bertino B, Blanchet-Réthoré S, Carlavan I, et al. Non-clinical and human pharmacology of potent and selective topical retinoic acid receptor γ-agonist trifarotene. Br J Dermatol. 2018; 179: 442-456. As you can see? How about another R29 goodness, here?